| 摘要 |
Provided are a propenohydroxamic acid derivative represented by the following formula (1): [wherein, R<1 >represents a hydrogen atom, an alkyl group or a halogen atom, R<2 >represents a cycloalkyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, R<3 >represents a hydrogen atom or a halogen atom, R<4 >represents a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkenyl group, R<5 >represents R<6>CO-, R<6>SO2-, R<6>NHCO- or R<6>NHCS- (in which, R<6 >represents a substituted or unsubstituted alkyl or cycloalkyl group, a cyclic amino group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group), R<7 >represents a hydrogen atom or a protecting group and A represents CH, a nitrogen atom or an oxidized nitrogen atom], or salt thereof; and a medicament containing the propenohydroxamic acid derivative or salt thereof. The compound (1) or salt thereof has excellent TACE inhibitory activity and is therefore useful as a medicament for preventing and/or treating diseases such as septicemia, rheumatoid arthritis, osteoarthritis, infectious diseases, autoimmune diseases, malignant neoplasm, collagenosis, chronic ulcerative colitis, MOF and insulin-independent diabetes.
|
